---
title: "Molecular Templates (MTEM.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/MTEM.US.md"
symbol: "MTEM.US"
name: "Molecular Templates"
industry: "Biotechnology"
---

# Molecular Templates (MTEM.US)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |

## Company Profile

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technolo...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-20T04:30:12.000Z

**Overall: C (0.59)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 189 / 403 |
| Industry Median | D |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -49.41% |  |
| Net Profit YoY | 66.55% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 25.47M |  |


**Multi Score**: C

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 1994.38% | A |
| Profit Margin | -61.35% | E |
| Gross Margin | -844.41% | E |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -49.41% | E |
| Net Profit YoY | 66.55% | A |
| Total Assets YoY | -24.82% | E |
| Net Assets YoY | 181.94% | A |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -163.00% | D |
| OCF YoY | -49.41% | E |

#### Operating Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.82 | B |

#### Debt Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 73.36% | D |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Molecular Templates",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "1994.38%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-61.35%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "-844.41%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-49.41%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "66.55%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-24.82%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "181.94%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-163.00%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "-49.41%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "B",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.82",
          "rating": "B"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "D",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "73.36%",
          "rating": "D"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | Adma Biologics (US.ADMA) | A | A | A | B | B | A |
| 02 | Kiniksa Pharmaceuticals (US.KNSA) | B | A | A | B | A | A |
| 03 | Stoke Therapeutics (US.STOK) | A | A | B | A | B | A |
| 04 | Rigel Pharma (US.RIGL) | A | A | A | C | B | A |
| 05 | OpGen (US.OPGN) | B | A | A | A | B | A |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 0.00 | 62/604 | - | - | - |
| PB | 0.00 | 3/604 | 0.00 | 0.00 | 0.00 |
| PS (TTM) | 0.00 | 2/604 | 0.00 | 0.00 | 0.00 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/MTEM.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/MTEM.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/MTEM.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.